Frontiers in Immunology (Sep 2023)

Corrigendum: Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation

  • Guo-Qing Tang,
  • Yalan Tang,
  • Ketki Dhamnaskar,
  • Michelle D. Hoarty,
  • Rohit Vyasamneni,
  • Douangsone D. Vadysirisack,
  • Zhong Ma,
  • Nanqun Zhu,
  • Jian-Guo Wang,
  • Charlie Bu,
  • Bestine Cong,
  • Elizabeth Palmer,
  • Petra W. Duda,
  • Camil Sayegh,
  • Alonso Ricardo

DOI
https://doi.org/10.3389/fimmu.2023.1282155
Journal volume & issue
Vol. 14

Abstract

Read online

No abstracts available.

Keywords